Thesis13 Apr 2026 09:22
To fill this quiet time.. I'll post what I believe is quite a realistic picture for the next two years.
Anyone who looks at AMP right now should see that Uskmouth AW1 is the most important project at this point in time. Leaving aside MeyGen as this is a "maybe" multiplier, but a highly uncertain one.
So, with that in mind.. AW1 should be powered up around October (plus/minus). With fingers crossed.. if there are no delays or catastrophes, the share price should see a good re-rate just for the completion of AW1 - assuming we get the ~£9m EBITDA.
Apparently, 10x is a mid-level multiple for this sector. Can be higher, can be lower. So £9m x 10 = ~£90m enterprise value for AW1 once fully operational and de-risked.
Importantly, this is not something to simply add on top of today’s £20m market cap, because part of AW1 is already being priced in today on a risk-adjusted basis. The uplift comes from moving from “development probability” to “operational certainty”.
In other words: AW1 is likely the first major step in re-rating from current levels, rather than a pure additive jump.
But, of course, there is more.
AW2 would also provide ~£8 to £12m EBITDA. Same for Mey BESS which should bring ~£5 to £10m.
So..
AW1: £70m to £100m
AW2: £80m to £120m
Mey BESS: £50m to £100m
Low: ~£200m
Mid: ~£260m
High: ~£320m
From there we need to consider that these are enterprise values, and that project-level debt will sit against them. We also need to assume that future growth (AW2 / Mey) will not be purely equity-funded, so some dilution should be expected over time, which will affect per-share outcomes.
Putting this together, a realistic range could still imply:
Low: ~£50m equity value
Mid: ~£100m equity value
High: ~£150m equity value
Which translates roughly into:
~7.5p to ~22.5p per share (depending on dilution and execution)
Note: That's not the valuation of today of course, but a simplified forward scenario of what I think a reasonable 1–2 year outcome range could look like if execution goes broadly to plan and financing is achievable.
Also: This does not include AW3 or any other potential that Uskmouth may provide as a platform and also MeyGen is essentially left out here in terms of future potential.